- Mots-clés > access to medicines
- Mots-clés > donation - pharmaceutical industry programs
- Mots-clés > pharmaceutical companies - social business initiatives
- Mots-clés > pharmaceutical industry
- Mots-clés > pharmaceutical industry - performance
- Mots-clés > pharmaceutical industry - role
- Mots-clés > pharmaceutical industry partnership
- Mots-clés > pharmaceutical industry social responsibility
- Mots-clés > Public-Private Partnerships (PPPs)
- Mots-clés > Quality Risk Management (QRM)
(2017; 8 pages) [French]
In recent years, there has been an increase in the number and scope of activities carried out by pharmaceutical and medical device companies to facilitate access to medicines and other health technologies and strengthen health systems in low- and middle-income countries. These initiatives follow a call for more commitment from the private and public sectors to contribute to Universal Health Coverage.
Despite the proliferation of these initiatives, no global framework or guidelines exist to guide governments in their development, implementation and regulation. Thus, the challenges for governments working with industry are: 1) ensuring public accountability; 2) sharing and managing risks; 3) monitoring and evaluating performance; 4) ensuring good governance; and 5) long-term sustainability.
This policy brief was therefore designed for governments to highlight potential risks and benefits of these initiatives and to provide guidance to effectively respond to industry initiatives related to medicines and other health products.